Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: A position statement of the korean diabetes association

Seung Hyun Ko, Kyu Yeon Hur, Sang Youl Rhee, Nan Hee Kim, Min Kyong Moon, Seok O. Park, Byung Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

In 2017, the Korean Diabetes Association (KDA) published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). The KDA regularly updates its Clinical Practice Guidelines, but since the last update in 2015, many results from clinical trials have been introduced, and domestic data from studies performed in Korean patients with T2DM have been published. Recently, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations. Additionally, new data from clinical trials using dipeptidyl peptidase 4 inhibitors and thiazolidinediones in Korean patients with T2DM were added. Following a systematic review and assessment of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the use of antihyperglycemic agents and revised the treatment algorithm for Korean adult patients with T2DM.

Original languageEnglish
Pages (from-to)947-958
Number of pages12
JournalKorean Journal of Internal Medicine
Volume32
Issue number6
DOIs
Publication statusPublished - 2017 Nov

Fingerprint

Hypoglycemic Agents
Type 2 Diabetes Mellitus
Sodium-Glucose Transport Proteins
Clinical Trials
Dipeptidyl-Peptidase IV Inhibitors
Therapeutics
Thiazolidinediones
Practice Guidelines

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Ko, Seung Hyun ; Hur, Kyu Yeon ; Rhee, Sang Youl ; Kim, Nan Hee ; Moon, Min Kyong ; Park, Seok O. ; Lee, Byung Wan ; Kim, Hyun Jin ; Choi, Kyung Mook ; Kim, Jin Hwa. / Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017 : A position statement of the korean diabetes association. In: Korean Journal of Internal Medicine. 2017 ; Vol. 32, No. 6. pp. 947-958.
@article{8633f7a6b9324347a1b6af0f6e212195,
title = "Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: A position statement of the korean diabetes association",
abstract = "In 2017, the Korean Diabetes Association (KDA) published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). The KDA regularly updates its Clinical Practice Guidelines, but since the last update in 2015, many results from clinical trials have been introduced, and domestic data from studies performed in Korean patients with T2DM have been published. Recently, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations. Additionally, new data from clinical trials using dipeptidyl peptidase 4 inhibitors and thiazolidinediones in Korean patients with T2DM were added. Following a systematic review and assessment of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the use of antihyperglycemic agents and revised the treatment algorithm for Korean adult patients with T2DM.",
author = "Ko, {Seung Hyun} and Hur, {Kyu Yeon} and Rhee, {Sang Youl} and Kim, {Nan Hee} and Moon, {Min Kyong} and Park, {Seok O.} and Lee, {Byung Wan} and Kim, {Hyun Jin} and Choi, {Kyung Mook} and Kim, {Jin Hwa}",
year = "2017",
month = "11",
doi = "10.3904/kjim.2017.298",
language = "English",
volume = "32",
pages = "947--958",
journal = "Korean Journal of Internal Medicine",
issn = "1226-3303",
publisher = "Korean Association of Internal Medicine",
number = "6",

}

Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017 : A position statement of the korean diabetes association. / Ko, Seung Hyun; Hur, Kyu Yeon; Rhee, Sang Youl; Kim, Nan Hee; Moon, Min Kyong; Park, Seok O.; Lee, Byung Wan; Kim, Hyun Jin; Choi, Kyung Mook; Kim, Jin Hwa.

In: Korean Journal of Internal Medicine, Vol. 32, No. 6, 11.2017, p. 947-958.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017

T2 - A position statement of the korean diabetes association

AU - Ko, Seung Hyun

AU - Hur, Kyu Yeon

AU - Rhee, Sang Youl

AU - Kim, Nan Hee

AU - Moon, Min Kyong

AU - Park, Seok O.

AU - Lee, Byung Wan

AU - Kim, Hyun Jin

AU - Choi, Kyung Mook

AU - Kim, Jin Hwa

PY - 2017/11

Y1 - 2017/11

N2 - In 2017, the Korean Diabetes Association (KDA) published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). The KDA regularly updates its Clinical Practice Guidelines, but since the last update in 2015, many results from clinical trials have been introduced, and domestic data from studies performed in Korean patients with T2DM have been published. Recently, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations. Additionally, new data from clinical trials using dipeptidyl peptidase 4 inhibitors and thiazolidinediones in Korean patients with T2DM were added. Following a systematic review and assessment of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the use of antihyperglycemic agents and revised the treatment algorithm for Korean adult patients with T2DM.

AB - In 2017, the Korean Diabetes Association (KDA) published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). The KDA regularly updates its Clinical Practice Guidelines, but since the last update in 2015, many results from clinical trials have been introduced, and domestic data from studies performed in Korean patients with T2DM have been published. Recently, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations. Additionally, new data from clinical trials using dipeptidyl peptidase 4 inhibitors and thiazolidinediones in Korean patients with T2DM were added. Following a systematic review and assessment of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the use of antihyperglycemic agents and revised the treatment algorithm for Korean adult patients with T2DM.

UR - http://www.scopus.com/inward/record.url?scp=85034588807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034588807&partnerID=8YFLogxK

U2 - 10.3904/kjim.2017.298

DO - 10.3904/kjim.2017.298

M3 - Review article

C2 - 29056038

AN - SCOPUS:85034588807

VL - 32

SP - 947

EP - 958

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

SN - 1226-3303

IS - 6

ER -